Sign up USA
Proactive Investors - Run By Investors For Investors

AusCann Group Holdings makes new appointments

An alternate director and chief medical advisor have been appointed.
AusCann Group Holdings makes new appointments
Shares are 75% above their February listing price

AusCann Group Holdings (ASX:AC8) has appointed a new alternate director to its board and new chief medical advisor to its staff.

Bruce Linton, a non-executive director has appointed David Pryce to act as his alternate director effective from today.

Pryce is currently vice president of international market expansion and global government relations at Canopy Growth Corp., the largest cannabinoid medicine producer in North America.

In this capacity, Pryce is responsible for taking the company into new markets, growing footprint and driving its global expansion.

Elaine Darby, managing director, commented: “We have worked with David for some time on a management level and the board will greatly benefit from his experience given our international expansion objectives.

“These objectives include expansion into the South American market with our existing Chilean operation and investigating international opportunities with our strategic partner Tasmanian Alkaloids.”


Chief medical advisor

International medical cannabis expert, Dr Danial Schecter has been appointed chief medical advisor.

Doctor training and awareness forms a key part of the company’s strategy to educate the medical community on the potential benefits of cannabinoids as therapeutic agents to treat certain conditions, such as chronic pain.

Schecter believes Australian physicians have not been taught about the endocannabinoid system in medical school or post-graduate training and there are no formal learning pathways.

Because of this, a potentially valuable medication is not going to be prescribed to a large portion of the population who could significantly benefit from this.

In order to rectify this situation, to allow patients access to cannabinoid medicines, Schecter believes it is crucial to support medical education

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use